Mwyngil Therapeutics Takes Unconventional Approach to Obesity Treatment
Mwyngil Therapeutics, a new biotech startup, is tackling obesity with a unique approach that doesn't involve the popular GLP-1 target. CEO Luba Greenwood explains why the company is taking a different path in the multibillion-dollar weight loss market.